Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,505,416
  • Shares Outstanding, K 201,440
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.86
  • Price/Sales 5.55
  • Price/Cash Flow 12.49
  • Price/Book 5.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 6.79
  • Number of Estimates 26
  • High Estimate 7.19
  • Low Estimate 6.49
  • Prior Year 6.31
  • Growth Rate Est. (year over year) +7.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
318.52 +0.47%
on 10/19/18
358.41 -10.71%
on 10/01/18
-18.89 (-5.58%)
since 09/19/18
3-Month
318.52 +0.47%
on 10/19/18
388.67 -17.66%
on 07/25/18
-38.09 (-10.64%)
since 07/19/18
52-Week
249.17 +28.43%
on 04/24/18
388.67 -17.66%
on 07/25/18
-22.40 (-6.54%)
since 10/19/17

Most Recent Stories

More News
After Yesterday's Decline of 2.55%, Biogen Inc Offers Investors Better Value

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.02 to a high of $327.12. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $328.00...

BIIB : 320.30 (-2.98%)
Biogen Inc Set to Possibly Rebound After Yesterday's Selloff of 2.55%

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $319.02 to a high of $327.12. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $328.00...

BIIB : 320.30 (-2.98%)
Alkermes Boasts Strong Portfolio and Impressive Pipeline

Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

MRK : 72.41 (+0.28%)
LLY : 112.16 (-1.01%)
ALKS : 40.24 (-1.37%)
BIIB : 320.30 (-2.98%)
Next Support Level for Biogen Inc (BIIB) is $322.19

Biogen Inc (NASDAQ:BIIB) has opened bearishly below the pivot of $331.98 today and has reached the first level of support at $326.17. Should the shares continue to fall, the support pivots of $322.19...

BIIB : 320.30 (-2.98%)
Biogen to Present Data from Alzheimer's Disease Portfolio at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Meeting

EMBARGOED FOR DISTRIBUTION Please note CTAD embargo policy: All materials submitted to CTAD are embargoed for publication and broadcast until the officially scheduled date and time of presentation, symposia...

BIIB : 320.30 (-2.98%)
Biogen and Samsung Bioepis Announce European Launch of IMRALDI(TM)(adalimumab), Solidifying Leadership in European Anti-TNF Market

--Biogen and Samsung Bioepis were the first in Europe to receive approvals for biosimilars referencing the three most prescribed anti-TNF medicines in Europe.

BIIB : 320.30 (-2.98%)
IMRALDI(TM), Biogen's Adalimumab Biosimilar Referencing Humira(R), Is Launched in the European Union

- IMRALDITM is approved in the European Union for the same 14 complex autoimmune conditions as its reference product

BIIB : 320.30 (-2.98%)
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet

Corium International (CORI) announces merger agreement with Gurnet Point Capital. The deal values Corium at $12.50 per share in cash and will take the company private.

AGN : 189.19 (+0.16%)
RHHBY : 30.6000 (+2.56%)
CORI : 12.55 (-0.16%)
BIIB : 320.30 (-2.98%)
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.

NVS : 87.22 (+1.14%)
TEVA : 21.48 (+0.99%)
RHHBY : 30.6000 (+2.56%)
BIIB : 320.30 (-2.98%)
Novartis Presents Data on Multiple Sclerosis Drug Gilenya

Novartis (NVS) announces encouraging data from a late-stage trial, ASSESS, on multiple sclerosis drug, Gilenya, which further reinforces its efficacy in treating relapses.

NVS : 87.22 (+1.14%)
MNTA : 13.71 (-6.99%)
TEVA : 21.48 (+0.99%)
BIIB : 320.30 (-2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 341.77
1st Resistance Point 335.96
Last Price 320.52
1st Support Level 326.17
2nd Support Level 322.19

See More

52-Week High 388.67
Fibonacci 61.8% 335.38
Last Price 320.52
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar